Cost-effective MHz rate Optical Coherence Tomography for biomedical applications

适用于生物医学应用的经济高效的 MHz 速率光学相干断层扫描

• 批准号: 8781221
• 负责人: Roman Kuranov
• 金额: $ 20.7万
• 依托单位: WASATCH PHOTONICS, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2015-12-01
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8781221
• 关键词: Adopted; Air; Area; Blindness; Buffers; Businesses; Cardiovascular Diseases; Clinical; Complex; Computer software; Data; Dentistry; Dermatology; Development; Devices; Diagnostic; Disease; Doctor of Philosophy; Electrical Engineering; Elements; Eye; Fiber; Fiber Optics; Functional Imaging; Germany; Health Services; Image; Industry; Insurance; Japan; Lasers; Lead; Length; Malignant Neoplasms; Marketing; Mechanics; Morphologic artifacts; Motion; Ophthalmology; Optical Coherence Tomography; Optics; Outcome; Patients; Performance; Pharmacy facility; Phase; Positioning Attribute; Process; Quality of life; Relative (related person); Reporting; Research; Resolution; Retinal; Sales; Sampling; Scanning; Scientist; Signal Transduction; Silicon; Small Business Innovation Research Grant; Software Engineering; Speed; Structure; System; Systems Development; Technology; Testing; Three-Dimensional Image; Time; arm; base; clinical application; commercial application; commercialization; cost; cost effective; design; detector; experience; imaging modality; improved; in vivo; innovation; instrument; meetings; novel strategies; optical imaging; photonics; prototype; public health relevance; social; success; tool

DESCRIPTION (provided by applicant): During this SBIR Phase I project we propose to build and test in phantoms a prototype of an innovative cost-effective Optical Coherence Tomography (OCT) system with a 10X increase in acquisition rate compared to commercially available systems. Further development may add an additional 10X increased acquisition rate for a total of 100X. Current market demand for Mega in-depth profiles (A-scans) per second OCT in biomedical applications is driven by the inability of current 100,000 A-scans/second OCT systems to provide motion free 3-D images and to cover target area within allowable imaging times. Increasing imaging speed to MHz rates also enables functional imaging that is not currently possible. Finally, MHz imaging speed means less suffering for patients and faster exams means less cost for both patients and insurance companies that will lead to wider acceptance of the OCT imaging in biomedical and clinical applications. There are research OCT systems with MHz acquisition rates from two groups: one in Germany and one in Japan. These systems have shown the value through dramatic imaging improvements available with MHz rate OCT. However, these research MHz rate OCT systems are currently too expensive and unstable for commercialization. Furthermore, the designs being implemented do not have a clear development trajectory to commercial viability. Therefore a novel approach to MHz OCT is needed. We believe our design approach combines the needed system performance with a clear path to successful commercialization. Social benefits of this project include the commercialization of a new product with broad biomedical, clinical and industry impact. Improved imaging capabilities has a great potential to improve our quality of life by first, improving the outcome of devastating diseases including blindness, cancer, cardiovascular diseases among others; and secondly, by enabling better quality in pharmacy, coating quality and micro-elements.

描述（由申请人提供）：在SBIR第一阶段项目期间，我们建议在虚拟环境中构建和测试一种创新的具有成本效益的光学相干断层扫描（OCT）系统的原型，与市售系统相比，其采集速率增加了10倍。进一步的开发可能会增加额外的10倍增加采集速率，总计100倍。当前市场对生物医学应用中每秒百万次深度轮廓（A扫描）OCT的需求是由当前100，000次A扫描/秒OCT系统无法提供无运动3D图像并在允许的成像时间内覆盖目标区域所驱动的。将成像速度提高到MHz速率还可以实现目前不可能实现的功能成像。最后，MHz成像速度意味着患者的痛苦更少，更快的检查意味着患者和保险公司的成本更低，这将导致OCT成像在生物医学和临床应用中得到更广泛的接受。 有两组具有MHz采集率的研究OCT系统：一组在德国，一组在日本。这些系统已经通过MHz速率OCT的显著成像改进显示了价值。然而，这些研究MHz速率OCT系统目前太昂贵且不稳定，无法商业化。此外，正在实施的设计没有明确的商业可行性发展轨迹。因此，需要一种新的MHz OCT方法。我们相信，我们的设计方法将所需的系统性能与成功商业化的清晰路径相结合。 该项目的社会效益包括具有广泛生物医学，临床和行业影响的新产品的商业化。改进的成像能力具有很大的潜力，可以改善我们的生活质量，首先，改善包括失明，癌症，心血管疾病等在内的毁灭性疾病的结果;其次，通过提高制药，涂层质量和微量元素的质量。